IL6 and major depressive disorder: Subsequent research showed that administration of low-dose endotoxin (e.g., lipopolysaccharide (LPS)) increases systemic markers of inflammation including tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) and symptoms of depression (41).